Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort studyWouter Froyman, D. Timmerman, Francesco Leone et al.|The Lancet Oncology|2019Cited by 188
Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort studyBen Van Calster, D. Timmerman, L. Valentin et al.|BMJ|2020Cited by 124
Immunocompetent Mouse Models in the Search for Effective Immunotherapy in GlioblastomaRoxanne Wouters, An Coosemans|Cancers|2020Cited by 36
Combining conventional therapy with immunotherapy: A risky business?An Coosemans, Ignace Vergote, Ann Vankerckhoven et al.|European Journal of Cancer|2019Cited by 31
TIM3 Checkpoint Inhibition Fails to Prolong Survival in Ovarian Cancer-Bearing MiceYani Berckmans, An Coosemans|Cancers|2024Cited by 2